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Abstract
The purpose of the study was to synthesize potent antimicrobial and cytotoxic agents by condensing sulphanilamide with 1,2,3,4-
tetrahydropyrimidines. A new series of novel sulphanilamide condensed 1,2,3,4-tetrahydropyrimidines was prepared by reacting
N-[(4-aminophenyl) sulphonyl]-3-oxobutanamide with urea/thiourea and aryl aldehyde in the presence of a catalytic amount of
laboratory prepared chlorosulphonic acid as an efficient catalyst. The chemical structures of the synthesized compounds (7a-r)
were confirmed by TLC, and the compounds were characterized by IR, 1H NMR, mass spectra and elemental analysis. The
synthesized compounds were evaluated for antimicrobial activity against the Gram-positive bacteria Bacillus  subtilis  and the Gram-
negative bacteria Escherichia  coli  and for cytotoxicity against Vero cells. These compounds exhibited weak, moderate, or high
antimicrobial activities and cytotoxicity. In particular, compound 7p exhibited the best antimicrobial activity and cytotoxicity
of all the 1,2,3,4-tetrahydropyrimidine derivatives with antimicrobial activity MIC values of 11.4 M and 12.1 M against B.
subtilis  and E.  coli, respectively, and a cytotoxicity CTC50 value of 19.0 M against Vero  cells. The sulphanilamide condensed
1,2,3,4-tetrahydropyrimidines generated here might prove interesting as potential antimicrobial cytotoxic agents.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
Throughout history, there has been a constant battle
between humans and the multitude of microorganisms
that cause infections and diseases. The treatment of
bacterial infections remains a challenging therapeutic
problem because of emerging infectious diseases and
the increasing number of multidrug-resistant microbial
pathogens. Despite the many antibiotics and chemother-behalf of Taibah University. This is an open access article under the
apeutics available, the emergence of old and new
antibiotic-resistant bacterial strains in the last decades
has generated a substantial need for new classes of
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nti-bacterial agents [1]. The increasing incidence of
nfection caused by the rapid development of bacterial
esistance to most known antibiotics is a serious health
roblem. While many factors may be responsible for
utations in microbial genomes, the incorrect use of
ntibiotics has been thoroughly demonstrated to greatly
ncrease the development of resistant genotypes. The
eed for effective therapies against multidrug-resistant
acterial strains has stimulated research into the design
nd synthesis of novel antimicrobial molecules [2].
In 1893, Pietro Biginelli reported the first synthe-
is of 3,4-dihydropyrimidin-2 (1H)-ones by one-pot
yclocondensation of an aromatic aldehyde, ethyl ace-
oacetate, and urea in ethanol solution using thermal
eating [3]. In recent years, the interest in dihydropy-
imidines (DHPMs) has increased rapidly because of
he structural resemblance of DHPMs with clinically
mportant Hantzsch pyridines [4,5]. The biologically
ctive dihydropyridine molecules contain a 4-phenyl
ing substituent positioned above and in the verti-
al plane of the 1,4-dihydropyridine ring, which has
 flattened boat conformation [6]. Pyrimidine deriva-
ives are a diverse and interesting group of drugs
hat have enormously important biological activities.
ihydropyrimidines and their derivatives have attracted
ncreasing interest due to their therapeutic and pharma-
eutical properties, such as antiviral, antitubercular [7,8],
nd antimicrobial [9–13] activities, antagonism of the
uman adenosine A2A receptor [14], cyclooxygenase-
 inhibitory activity [15,16], tyrosine kinase inhibitory
ctivity [17], antiamoebic activity [18], and cytotoxicity
19,20].
The chemical structure of sulphanilamide make
ts a valuable molecular template for the develop-
ent of agents with a wide variety of biological
ctivities [21]. Tetrahydropyrimidines are structurally
imilar to dihydropyrimidines. Thus, synthesizing new
ongeners by incorporating sulphanilamide with 1,2,3,4-
etrahydropyrimidinone moieties in a single molecular
ramework and evaluating their antimicrobial activities
nd cytotoxicities was considered to be worthwhile.
.  Experimental
.1.  Materials  and  methods
All chemicals were supplied by E. Merck (Germany)
nd S.D fine chemicals (India). Melting points were
etermined by the open tube capillary method and were
ncorrected. The purity of the compounds was confirmed
sing thin layer chromatography (TLC) plates (silica
el G) in a solvent system, ethanol, chloroform, ethylersity for Science 11 (2017) 46–56 47
acetate (5:3:2), and spots were visualized under iodine
vapours or UV light. IR spectrums were obtained using
a Perkin-Elmer 1720 FT-IR spectrometer (KBr Pellets).
1H NMR spectra were recorded using a Bruker DRX-300
(300 MHz FT-NMR) spectrometer with DMSO-d6 as the
solvent and TMS as the internal standard. Mass spectra
were obtained using Shimadzu LCMS 2010A software
and the ESI ionization technique. Elemental analyses (C,
H, and N) were performed using a Perkin Elmer model
240C analyser.
2.2.  Preparation  of  N-[(4-aminophenyl)
sulphonyl]-3-oxobutanamide  (3)
Sulphanilamide 1 (0.01 M), ethyl acetoacetate 2
(0.01 M), and a catalytic amount of anhydrous potas-
sium carbonate were mixed in the presence of 10 ml
ethanol (95%) and refluxed for approximately 2.5 h. The
colourless liquid that formed was then heated in a water
bath to remove the alcohol that formed during the reac-
tion. After allowing the reaction mixture to cool, crude
crystals were obtained. Purification was performed by
stirring crude crystals with cold diethyl ether for approx-
imately 15 min using a mechanical stirrer. The solution
was allowed to stand for 15 min and then filtered, result-
ing in the pure third compound of N-[(4-aminophenyl)
sulphonyl]-3-oxobutanamide 3.
2.3.  Preparation  of  1,2,3,4-tetrahydropyrimidines
by microwave  irradiation  method  (7a-r)
The mixture of N-[(4-aminophenyl) sulphonyl]-3-
oxobutanamide (0.005 M), urea/thiourea (0.0075 M),
and aryl aldehyde (0.005 M) with a catalytic amount of
chlorosulphonic acid in 10 ml of ethanol was subjected
to microwave irradiation (300 W) for 14 min with 10 s
intervals. The reactions were monitored with TLC using
the ethanol, chloroform, ethyl acetate (4:3:3); solvent
system. After the reaction was completed, the reaction
mixture was cooled in a refrigerator and filtered. The
precipitate obtained was washed thoroughly with water
to remove unreacted urea/thiourea and dried. The crude
solid product was crystallized with ethanol to generate
the pure compounds (7a-r).
2.4.  Analytical  data
2.4.1.  N-(3-oxobutanoyl)  pyrazine-2-carboxamide
(3)
Colourless solid, M.P: 185–187 ◦C; yield: 63%; IR
(KBr, cm−1): 3386 (N H), 2942 (Ali C H), 1726
(C O, ketone), 1684e (C O, amide), 1585 (C C), 1358
ah Univ48 K. Elumalai et al. / Journal of Taib
(C N), 1052 (S O); 1H NMR (DMSO-d6) δ: 2.07 (s,
3H, CH3), 3.39 (s, 2H, CH2), 4.08 (s, 2H, NH2), 6.79 (d,
2H, Ar H), 7.74 (d, 2H, Ar H), 8.09 (s, 1H, NH); cal-
culated for C10H12N2O4S: C, 46.87; H, 4.72; N, 10.93;
found C, 46.92; H, 4.78; N, 10.98.
2.4.2. N-[(4-aminophenyl)  sulphonyl]
-6-methyl-2-Oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide
(7a)
Colourless solid, M.P: 298–300 ◦C; yield: 73%;
IR (KBr, cm−1): 3282 (N H), 3185(Ar C H), 2936
(Ali C H), 1677 (C O, amide), 1588 (C C), 1257
(O C), 1068 (S O); 1H NMR (DMSO-d6) δ: 1.78 (s,
3H, CH3), 4.04 (s, 2H, NH2), 5.41 (s, 1H, CH), 6.12
(s, 1H, NH), 6.15 (s, 1H, NH), 6.77 (d, 2H, Ar H),
7.06–7.15 (m, 5H, Ar H), 7.71 (d, 2H, Ar H), 8.11
(s, 1H, NH); MS (m/z): (M+1) calculated 387.11; found
387.16; calculated for C18H18N4O4S: C, 55.95; H, 4.70;
N, 14.50; found C, 55.89; H, 4.75; N, 14.56.
2.4.3.  N-[(4-aminophenyl)
sulphonyl]-6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide
(7b)
Colourless solid, M.P: 326–328 ◦C; yield: 76%;
IR (KBr, cm−1): 3266 (N H), 3178(Ar C H), 2934
(Ali C H), 1679 (C O, amide), 1591 (C C), 1867
(C S), 1158 (O C), 1044 (S O); 1H NMR (DMSO-
d6) δ: 1.76 (s,3H, CH3), 2.12 (s, 1H, NH), 2.18 (s, 1H,
NH), 4.11 (s, 2H, NH2), 4.67 (s, 1H, CH), 6.77 (d, 2H,
Ar H), 7.06–7.15 (m, 5H, Ar H), 7.71 (d, 2H, Ar H),
8.06 (s, 1H, NH); MS (m/z): (M+1) calculated 403.08;
found 403.03; calculated for C18H18N4O3S2: C, 53.71;
H, 4.51; N, 13.92; found C, 53.76; H, 4.57; N, 13.87.
2.4.4. N-[(4-aminophenyl)
sulphonyl]-6-methyl-4-(2-nitrophenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7c)
Colourless solid, M.P: 337–339 ◦C; yield: 78%; IR
(KBr, cm−1): 3347 (N H), 3263 (Ar C H), 2982
(Ali C H), 1676 (C O, amide), 1574 (C C), 1384
(O C), 1053 (S O); 1H NMR (DMSO-d6) δ: 1.74 (s,
3H, CH3), 4.06 (s, 2H, NH2), 5.49 (s, 1H, CH), 6.07
(s, 1H, NH), 6.14 (s, 1H, NH), 6.81 (d, 2H, Ar H),
7.36 (d, 2H, Ar H), 7.58 (s, 1H, Ar H), 7.74 (d, 2H,
Ar H), 8.08 (s, 1H, Ar H), 8.15 (s, 1H, NH); MS (m/z):
(M+1) calculated 432.09; found 432.14; calculated for
C18H17N5O6S: C, 50.11; H, 3.97; N, 16.23; found C,
50.16; H, 3.91; N, 16.28.ersity for Science 11 (2017) 46–56
2.4.5.  N-[(4-aminophenyl)
sulphonyl]-6-methyl-4-(2-nitrophenyl)-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7d)
Colourless solid, M.P: 351–353 ◦C; yield: 76%; IR
(KBr, cm−1): 3273 (N H), 3147 (Ar C H), 2984
(Ali C H), 1678 (C O, amide), 1558 (C C), 1872
(C S), 1264 (O C), 1048 (S O); 1H NMR (DMSO-
d6) δ: 1.79 (s, 3H, CH3), 2.07 (s, 1H, NH), 2.15 (s, 1H,
NH), 4.03 (s, 2H, NH2), 4.42 (s, 1H, CH), 6.79 (d, 2H,
Ar H), 7.37 (d, 2H, Ar H), 7.55 (s, 1H, Ar H), 7.73
(d, 2H, Ar H), 8.04 (s, 1H, NH), 7.16 (s, 1H, Ar H);
MS (m/z): (M+1) calculated 448.07; found 448.13; cal-
culated for C18H17N5O5S2: C, 48.31; H, 3.83; N, 15.65;
found C, 48.36; H, 3.77; N, 15.71.
2.4.6. N-[(4-aminophenyl)
sulphonyl]-4-(2-chlorophenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7e)
Colourless solid, M.P: 336–338 ◦C; yield: 73%; IR
(KBr, cm−1): 3297 (N H), 3152 (Ar C H), 2967
(Ali C H), 1676 (C O amide), 1583 (C C), 1258
(C O), 1063 (S O); 1H NMR (DMSO-d6) δ: 1.76 (s,
3H, CH3), 4.04 (s, 2H, NH2), 5.51 (s, 1H, CH), 6.03
(s, 1H, NH), 6.11 (s, 1H, NH), 6.77 (d, 2H, Ar H),
7.01–7.17 (m, 4H, Ar H), 7.76 (d, 2H, Ar H), 8.16 (s,
1H, NH); MS (m/z): MS (m/z): (M+1) calculated 421.07;
found 421.02; calculated for C18H17ClN4O4S: C, 51.37;
H, 4.07; N, 13.31; found C, 51.31; H, 4.13; N, 13.36.
2.4.7. N-[(4-aminophenyl)
sulphonyl]-4-(2-chlorophenyl)-6-methyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7f)
Colourless solid, M.P: 361–363 ◦C; yield: 77%; IR
(KBr, cm−1): 3286 (N H), 3172 (Ar C H), 2978
(Ali C H), 1678 (C O, amide), 1582 (C C), 1868
(C S), 1175 (O C), 1069 (S O); 1H NMR (DMSO-d6)
δ: 1.74 (s,3H, CH3), 2.03 (s, 1H, NH), 2.09 (s, 1H, NH),
4.07 (s, 2H, NH2), 4.53 (s, 1H, CH), 6.73 (d, 2H, Ar H),
7.01–7.18 (m, 4H, Ar H), 7.73 (d, 2H, Ar H), 8.07 (s,
1H, NH); MS (m/z): (M+1) calculated 437.05; found
437.01; calculated for C18H17ClN4O3S2: C, 49.48; H,
3.92; N, 12.82; found C, 49.43; H, 3.96; N, 12.87.
2.4.8. N-[(4-aminophenyl)
sulphonyl]-6-methyl-4-(3-nitrophenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7g)
Colourless solid, M.P: 321–323 ◦C; yield: 72%; IR
(KBr, cm−1): 3286 (N H), 3159 (Ar C H), 2958
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Ali C H), 1676 (C O, amide), 1573 (C C), 1226
O C), 1044 (S O); 1H NMR (DMSO-d6) δ: 1.72 (s,
H, CH3), 4.06 (s, 2H, NH2), 5.48 (s, 1H, CH), 6.05
s, 1H, NH), 6.10 (s, 1H, NH), 6.78 (d, 2H, Ar H),
.43 (s, 1H, Ar H), 7.49 (s, 1H, Ar H), 7.71 (d, 2H,
r H), 8.04 (d, 2H, Ar H), 8.11 (s, 1H, NH); MS (m/z):
M+1) calculated 432.09; found 432.15; calculated for
18H17N5O6S: C, 50.11; H, 3.97; N, 16.23; found C,
0.16; H, 3.92; N, 16.29.
.4.9.  N-[(4-aminophenyl)
ulphonyl]-6-methyl-4-(3-nitrophenyl)-2-thioxo-
,2,3,4-tetrahydropyrimidine-5-carboxamide
7h)
Colourless solid, M.P: 364–366 ◦C; yield: 80%; IR
KBr, cm−1): 3294 (N H), 3176 (Ar C H), 2958
Ali C H), 1677 (C O, amide), 1584 (C C), 1848
C S), 1186 (O C), 1052 (S O); 1H NMR (DMSO-
6) δ: 1.71 (s, 3H, CH3), 2.04 (s, 1H, NH), 2.13 (s, 1H,
H), 4.05 (s, 2H, NH2), 4.46 (s, 1H, CH), 6.71 (d, 2H,
r H), 7.41 (s, 1H, Ar H), 7.48 (s, 1H, Ar H),7.77 (d,
H, Ar H), 8.07 (d, 2H, Ar H), 8.11 (s, 1H, NH); MS
m/z): (M+1) calculated 448.07; found 448.12; calcu-
ated for C18H17N5O5S2: C, 48.31; H, 3.83; N, 15.65;
ound C, 48.36; H, 3.87; N, 15.71.
.4.10. N-[(4-aminophenyl)
ulphonyl]-4-(3-chlorophenyl)-6-methyl-2-oxo-
,2,3,4-tetrahydropyrimidine-5-carboxamide
7i)
Colourless solid, M.P: 323–325 ◦C; yield: 75%; IR
KBr, cm−1): 3293 (N H), 3174 (Ar C H), 2965
Ali C H), 1676 (C O, amide), 1548 (C C), 1176
O C), 1061 (S O); 1H NMR (DMSO-d6) δ: 1.76 (s,3H,
H3), 4.08 (s, 2H, NH2), 5.38 (s, 1H, CH), 6.02 (s,1H,
H), 6.11 (s, 1H, NH), 6.76 (d, 2H, Ar H), 6.98–7.13
m, 4H, Ar H), 7.73 (d, 2H, Ar H), 8.14 (s, 1H, NH);
S (m/z): (M+1) calculated 421.07; found 421.03; cal-
ulated for C18H17ClN4O4S: C, 51.37; H, 4.07; N,
3.31; found C, 51.43; H, 4.12; N, 13.36.
.4.11.  N-[(4-aminophenyl)
ulphonyl]-4-(3-chlorophenyl)-6-methyl-2-thioxo-
,2,3,4-tetrahydropyrimidine-5-carboxamide
7j)
Colourless solid, M.P: 374–376 ◦C; yield: 77%; IR
KBr, cm−1): 3281 (N H), 3178 (Ar C H), 2968
Ali C H), 1683 (C O, amide), 1593 (C C), 1873
C S), 1188 (O C), 1045 (S O); 1H NMR (DMSO-
6) δ: 1.77 (s, 3H, CH3), 2.02 (s, 1H, NH), 2.08 (s,
H, NH), 4.06 (s, 2H, NH2), 4.42 (s, 1H, CH), 6.79ersity for Science 11 (2017) 46–56 49
(d, 2H, Ar H), 6.96–7.10 (m, 4H, Ar H), 7.72 (d, 2H,
Ar H), 8.03 (s, 1H, NH); MS (m/z): (M+1) calculated
437.05; found 437.11; calculated for C18H17ClN4O3S2:
C, 49.48; H, 3.92; N, 12.82; found C, 49.53; H, 3.97; N,
12.77.
2.4.12. N-[(4-aminophenyl)
sulphonyl]-4-(3-ﬂuorophenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7k)
Colourless solid, M.P: 331–333 ◦C; yield: 75%;
IR (KBr, cm−1): 3288 (N H), 3174(Ar C H), 2972
(Ali C H), 1677 (C O, amide), 1552 (C C), 1148
(O C), 1052 (S O); 1H NMR (DMSO-d6) δ: 1.73 (s,
3H, CH3), 4.05 (s, 2H, NH2), 5.43 (s, 1H, CH), 6.05
(s, 1H, NH), 6.13 (s, 1H, NH), 6.71 (d, 2H, Ar H),
6.79 (d, 2H, Ar H), 6.86 (s, 1H, Ar H), 7.17 (s, 1H,
Ar H), 7.75 (d, 2H, Ar H), 8.07 (s, 1H, NH); MS (m/z):
(M+1) calculated 405.10; found 405.16; calculated for
C18H17FN4O4S: C, 53.46; H, 4.24; N, 13.85; found C,
53.51; H, 4.29; N, 13.91.
2.4.13.  N-[(4-aminophenyl)
sulphonyl]-4-(3-ﬂuorophenyl)-6-methyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7l)
Colourless solid, M.P: 381–383 ◦C; yield: 79%; IR
(KBr, cm−1): 3282 (N H), 3194 (Ar C H), 2969
(Ali C H), 1679 (C O, amide), 1566 (C C), 1883
(C S), 1182 (O C), 1047 (S O); 1H NMR (DMSO-
d6) δ: 1.74 (s, 3H, CH3), 2.05 (s, 1H, NH), 2.11 (s, 1H,
NH), 4.02 (s, 2H, NH2), 4.53 (s, 1H, CH), 6.76 (d, 2H,
Ar H), 6.80 (d, 2H, Ar H), 6.89 (s, 1H, Ar H), 7.17 (s,
1H, Ar H), 7.77 (d, 2H, Ar H), 8.06 (s, 1H, NH); MS
(m/z): (M+1) calculated 421.07; found 421.13; calcu-
lated for C18H17FN4O3S2: C, 51.42; H, 4.08; N, 13.32;
found C, 51.47; H, 4.13; N, 13.39.
2.4.14. N-[(4-aminophenyl)
sulphonyl]-4-(4-chlorophenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7m)
Colourless solid, M.P: 339–341 ◦C; yield: 77%; IR
(KBr, cm−1): 3312 (N H), 3157 (Ar C H), 2972
(Ali C H), 1675 (C O, amide), 1558 (C C), 1184
(O C), 1055 (S O); 1H NMR (DMSO-d6) δ: 1.75 (s,
3H, CH3), 4.01 (s, 2H, NH2), 5.49 (s, 1H, CH), 6.08
(s, 1H, NH), 6.17 (s, 1H, NH), 6.76 (d, 2H, Ar H),
7.05 (d, 2H, Ar H), 7.18 (d, 2H, Ar H), 7.73 (d, 2H,
Ar H), 8.17 (s, 1H, NH); MS (m/z): (M+1) calculated
421.07; found 421.02; calculated for C18H17ClN4O4S:
ah Univ50 K. Elumalai et al. / Journal of Taib
C, 51.37; H, 4.07; N, 13.31; found C, 51.31; H, 4.12; N,
13.31.
2.4.15. N-[(4-aminophenyl)
sulphonyl]-4-(4-chlorophenyl)-6-methyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7n)
Colourless solid, M.P:371–373 ◦C; yield 80%; IR
(KBr, cm−1): 3298 (N H), 3178(Ar C H), 2972
(Ali C H), 1681 (C O, amide), 1558 (C C), 1846
(C S), 1182 (O C), 1065 (S O); 1H NMR (DMSO-d6)
δ: 1.76 (s, 3H, CH3), 2.03 (s, 1H, NH), 2.14 (s, 1H, NH),
4.06 (s, 2H, NH2), 4.51 (s, 1H, CH), 6.77 (d, 2H, Ar H),
7.05 (d, 2H, Ar H), 7.18 (d, 2H, Ar H), 7.73 (d, 2H,
Ar H), 8.04 (s, 1H, NH); MS (m/z): (M+1) calculated
437.05; found 437.11; calculated for C18H17ClN4O3S2:
C, 49.48; H, 3.92; N, 12.82; found C, 49.53; H, 3.96; N,
12.88.
2.4.16. N-[(4-aminophenyl)
sulphonyl]-4-(4-ﬂuorophenyl)-6-methyl-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7o)
Colourless solid, M.P: 324–326 ◦C; yield 73%; IR
(KBr, cm−1): 3294 (N H), 3188 (Ar C H), 2964
(Ali C H), 1679 (C O, amide), 1573 (C C), 1184
(O C), 1069 (S O); 1H NMR (DMSO-d6) δ: 1.75 (s,
3H, CH3), 4.01 (s, 2H, NH2), 5.49 (s, 1H, CH), 6.08 (s,
1H, NH), 6.17 (s, 1H, NH), 6.76 (d, 2H, Ar H), 7.05
(d, 2H, Ar H), 7.18 (d, 2H, Ar H), 7.73 (d, 2H, Ar H),
8.17 (s, 1H, NH); MS (m/z): (M+1) calculated 405.10;
found 405.14; calculated for C18H17FN4O4S: C, 53.46;
H, 4.24; N, 13.85; found C53.51; H, 4.18; N, 13.89.
2.4.17. N-[(4-aminophenyl)
sulphonyl]-4-(4-ﬂuorophenyl)-6-methyl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
(7p)
Colourless solid, M.P: 353–355 ◦C; yield 79%; IR
(KBr, cm−1): 3296 (N H), 3186 (Ar C H), 2982
(Ali C H), 1682 (C O, amide), 1585 (C C), 1861
(C S), 1186 (O C), 1053 (S O); 1H NMR (DMSO-d6)
δ: 1.72 (s, 3H, CH3), 2.06 (s, 1H, NH), 2.11 (s, 1H, NH),
4.09 (s, 2H, NH2), 4.47 (s, 1H, CH), 6.76 (d, 2H, Ar H),
6.90 (d, 2H, Ar H), 7.08 (d, 2H, Ar H), 7.71 (d, 2H,
Ar H), 8.11 (s, 1H, NH); MS (m/z): (M+1) calculated
421.07; found 421.13; calculated for C18H17FN4O3S2:
C, 51.42; H, 4.08; N, 13.32; found C, 51.47; H, 4.02; N,
13.36.ersity for Science 11 (2017) 46–56
2.4.18.  N-[(4-aminophenyl)
sulphonyl]-6-methyl-2-oxo-4-(pyridin-4-yl)-1,2,3,4-
tetrahydropyrimidine-5-carboxamide
(7q)
Colourless solid, M.P: 363–365 ◦C; yield 78%; IR
(KBr, cm−1): 3287 (N H), 3184 (Ar C H), 2984
(Ali C H), 1679 (C O, amide), 1574 (C C), 1179
(O C), 1058 (S O); 1H NMR (DMSO-d6) δ: 1.72 (s,
3H, CH3), 4.07 (s, 2H, NH2), 5.45 (s, 1H, CH), 6.02 (s,
1H, NH), 6.09 (s, 1H, NH), 6.79 (d, 2H, Ar H), 7.46
(d, 2H, Ar H), 7.78 (d, 2H, Ar H), 8.10 (s, 1H, NH),
8.64 (d, 2H, Ar H); MS (m/z): (M+1) calculated 388.10;
found 388.14; calculated for C17H17N5O4S: C, 52.70; H,
4.42; N, 18.08; found C, 52.76; H, 4.46; N, 18.14.
2.4.19. N-[(4-aminophenyl)  sulphonyl]
-6-methyl-4-(pyridin-4-yl)-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide
(7r)
Colourless solid, M.P: 317–319 ◦C; yield 73%;
IR (KBr, cm−1): 3258 (N H), 3192(Ar C H), 2936
(Ali C H), 1677 (C O, amide), 1583 (C C), 1891
(C S), 1138 (O C), 1064 (S O); 1H NMR (DMSO-d6)
δ: 1.74 (s, 3H, CH3), 2.03 (s, 1H, NH), 2.15 (s, 1H, NH),
4.04 (s, 2H, NH2), 4.52 (s, 1H, CH), 6.79 (d, 2H, Ar H),
7.45 (d, 2H, Ar H), 7.77 (d, 2H, Ar H), 8.06 (s, 1H,
NH), 8.65 (d, 2H, Ar H); MS (m/z): (M+1) calculated
355.09; found 355.14; calculated for C16H14N6O2S: C,
54.23; H, 3.98; N, 23.71; found C, 54.29; H, 3.95; N,
23.77.
2.5.  Antimicrobial  activity
The in  vitro  antibacterial activities of the novel
compounds against the Gram-positive bacteria Bacillus
subtilis and the Gram-negative bacteria Escherichia  coli
were tested by a standard serial dilution method using a
stock solutions of 100 g/ml [22,23]. Double strength
nutrient broth was used as the culture medium and
dimethyl sulphoxide (DMSO) was used as the solvent
control. The stock solutions of the test compounds were
serially diluted in test tubes containing 1 ml of ster-
ile medium to obtain different concentrations and then
inoculated with a 100 L of suspension of the indicated
microorganism in sterile saline. Norfloxacin was used
as the standard drug. The inoculated test tubes were
incubated at 37 ±  1 ◦C for 24 h.2.6.  In  vitro  cytotoxicity
Short-term in  vitro  cytotoxicity assays were per-
formed using Vero cells (African Monkey kidney cells)
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f the different compounds at different concentrations
2–500 g). Microscopic examinations were performed,
nd observations were recorded every 24 h. After, 72 h,
0% trichloroacetic acid (25 l) was added to each well,
nd the plates were incubated for 1 h at 4 ◦C. The super-
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plates were vigorously shaken for 5 min, and absorbance
was measured using a microtitre plate reader at 540 nm.
The mean absorbance of triplicate wells was recorded.
The mean absorbance value of cells grown in the absence
of the test compounds was taken as 100% cell survival
(control). The percentage growth inhibition was calcu-
lated using the following formula:
Growth inhibition% = 100 −
[
sample absorbance
control absorbance
]
× 100
3.  Results  and  discussion
A series of 18 novel sulphanilamide cyclocondensed
1,2,3,4-tetrahydropyrimidines of biological interest
were synthesized and evaluated for their antimicrobial
activities and cytotoxicities, and all compounds were
characterized by IR, 1H NMR, MS and elemental anal-
ysis of their structures.
 h, catalytic amount of anhydrous K2CO3 and 10 ml of ethanol (95%);
4 min.
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3.1.  Chemistry
Synthesis of 1,2,3,4-tetrahydropyrimidines using the
Biginelli synthetic protocol [24], which involves a one
pot multicomponent reaction, was performed follow-
ing the steps as outlined in Fig. 1. In the first step,
ethyl acetoacetate 2 and sulphanilamide 1 in the pres-
ence of a catalytic amount of anhydrous potassium
carbonate and 10 ml of ethanol (95%) were reacted
under net conditions resulting in the formation of
N-[(4-aminophenyl) sulphonyl]-3-oxobutanamide 3,
with a 63% yield. The -keto ester reacted more
readily with sulphonamide groups than with aromatic
primary amines. The N-[(4-aminophenyl) sulphonyl]-3-
oxobutanamide was used for the Biginelli condensation
reaction; it was reacted with urea/thiourea and aryl
aldehyde in the presence of a catalytic amount of chloro-
sulphonic acid. The advantages of using the catalyst were
better yields and allowing the reaction to occur without
dry solvents.
The one-pot synthetic method was developed for
1,2,3,4-tetrahydropyrimidines using microwave irradia-
tion. Microwave technology has been proven to be better
than conventional heating in the synthesis of these com-
pounds, as time and side products are decreased and yield
is improved with microwave irradiation. We succeeded
in widening the scope of the first step of the reaction by
using unconventional active methylene compounds. The
first step in the Biginelli reaction is the acid-catalysed
condensation of urea with the aldehyde [25]. This reac-
tion begins with protonation of the aldehyde by the acid
and is followed by an attack of the amine by urea. Then,
proton transfer steps result in the generation of a pro-
tonated alcohol, which is converted to water to form an
N-acyliminium ion intermediate [26]. The subsequent
enol form of the -Keto ester attacks the N-acyliminium
ion to generate an open chain ureide, which readily
cyclizes into a tetrahydropyrimidine (Fig. 2). The reac-
tion time was 14 min. The IR spectra of compounds 7a-r
are showed strong absorption bands for the amine group
(3258–3347 cm−1), amide group (1675–1683 cm−1),
aliphatic C H stretching (2934–2984 cm−1), aromatic
C H stretching (3152–3263 cm−1), aromatic C C
stretching (1548–1593 cm−1), C O (1138–1258 cm−1),
S O (1044–10690 cm−1), and C S (1846–1883 cm−1).
The 1H NMR spectra of compounds 7a-r showed a
methyl group protons singlet at (2.02–2.08 ppm), CH R
protons singlet at (5.39–5.52 ppm), aromatic protons
multiplet at (6.96–7.72 ppm) and amine protons singlet
at (8.92–10.26 ppm). The mass spectra and elemental
analysis results were within ±0.6% of the theoretical val-
ues. Eighteen substituted 1,2,3,4-tetrahydropyrimidines,ersity for Science 11 (2017) 46–56
named compounds 7a-r, were synthesized with yields
ranging from 72% to 80%. These conditions allow
this method to be applicable for the synthesis of
1,2,3,4-tetrahydropyrimidine-based heterocyclic com-
pounds. The present protocol is the best described for the
synthesis of 1,2,3,4-tetrahydropyrimidines. All reported
1,2,3,4-tetrahydropyrimidines compounds were found to
be novel and were not reported elsewhere.
3.2.  Antimicrobial  activity
The synthesized compounds were analyzed for
their in  vitro  antimicrobial activities against the Gram-
positive bacteria B.  subtilis  and the Gram-negative
bacteria E.  coli. Sulphanilamides are competitive
inhibitors of para-aminobenzoic acid (PABA), which
is essential for the biosynthesis of foliate coenzymes in
the synthesis of purine and pyrimidine bases in bacteria
[21]. The antimicrobial activities of the synthesized
compounds are shown in Fig. 3 and Table 1, and most of
the designed compounds exhibited good to moderate or
high antimicrobial activities against the Gram-positive
bacteria B.  subtilis  and the Gram-negative bacteria E.
coli. All 1,2,3,4-tetrahydropyrimidines were potent
antimicrobial agents, with MIC values ranging from
micromolar to submicromolar levels. In particular,
compound 7p showed the best antimicrobial activity of
all of the 1,2,3,4-tetrahydropyrimidine derivatives, with
MIC values of 11.4 M and 12.1 M for B.  subtilis  and
E. coli, respectively.
3.3.  In  vitro  cytotoxicity
The synthesized compounds were subjected to an
in vitro  cytotoxicity assay against Vero cells. The assay
was performed using the sulphorhodamine B (SRB)
method. These 1,2,3,4-tetrahydropyrimidines act pri-
marily by impairing cell reproductive integrity. Thus,
affected cells may remain alive and may continue to
perform many of their functions but are unable to repro-
duce successfully [20]. The synthesis of DNA, RNA
and other cell constituents may continue at normal rates.
However, the cell either fails to divide, forming a giant
cell, commences a division that cannot be completed,
or divides unsuccessfully, resulting in chromosomes
being unequally shared between the daughter cells or
being damaged in some way; these chromosomal lesions
may eventually cause cell death [22]. The investigated
compounds had a wide range of cytotoxic activities cat-
egorized as weak, moderate, or high. Compound 7p
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Fig. 2. General mechanism of Biginelli 1,2,3,4-tetrahydropyrimidines.
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xhibited significant cytotoxicity against Vero cells, with
 CTC50 value of 19.0 M (Fig. 4 and Table 1).
.4.  Structural  activity  relationshipBy analysing the activities of the synthesized
ompounds, the following structure activity relation-
hips (SAR) were obtained. The fifth position ofound s
pounds (7a-r) and Norfloxacin (Std.).
1,2,3,4-tetrahydropyrimidines contains a sulphanil-
amide group that contributes to their antimicrobial
activities and cytotoxicities [15]. Sulphanilamide
is a competitive inhibitor of PABA. Incorporation
of sulphanilamide in 1,2,3,4-tetrahydropyrimine
enhances its antimicrobial and cytotoxic potencies
because it enhances the affinity of the compound
for the PABA receptor. The 4th position of 1,2,3,
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Table 1
Synthesized 1,2,3,4-tetrahydropyrimidines: In Vitro antimicrobial and cytotoxicity.
General structure of 1,2,3,4-tetrahydropyrimidines
NH
N
H
CH3 X
O
NH
S
O
O
NH2
R
S. no Compound R X B. subtilis E. coli CTC50 (M)on
Vero Cells
MIC (M) MIC (M)
1 7a Phenyl O 78.5 80.4 484.4
2 7b Phenyl S 73.1 75.9 388.0
3 7c 2-Nitrophenyl O 61.4 65.2 299.3
4 7d 2-Nitrophenyl S 56.3 59.6 275.1
5 7e 2-Chlorophenyl O 52.1 55.7 304.7
6 7f 2-Chlorophenyl S 47.8 50.4 222.4
7 7g 3-Nitorophenyl O 24.3 26.8 180.9
8 7h 3-Nitorophenyl S 21.7 26.1 143.1
9 7i 3-Chlorophenyl O 19.1 20.8 123.8
10 7j 3-Chlorophenyl S 17.6 19.4 110.0
11 7k 3-Flurophenyl O 16.1 18.2 96.5
12 7l 3-Flurophenyl S 14.8 17.1 73.8
13 7m 4-Chlorophenyl O 13.9 15.3 42.8
14 7n 4-Chlorophenyl S 12.8 14.2 36.6
15 7o 4-Flurophenyl O 12.5 13.3 34.6
16 7p 4-Flurophenyl S 11.4 12.1 19.0
17 7q 4-Pyridyl O 15.6 18.9 74.9
18 7r 4-Pyridyl S 14.9 16.3 57.0
19 Norfloxacin Standard – 12.2 12.9 –
20 Tamoxifen Standard – – – 35.0
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-tetrahydropyrimine contains an aryl ring, specifically
 phenyl ring, and one hydrogen in that ring must
e substituted with a strong electron withdrawing
roup to improve the compound’s antimicrobial and
ytotoxic potencies; this substitution decreases the
lectron density in the aryl ring due to the inductive
ffect. Fluoride and chloride substitution at the 4th
osition of the phenyl ring generated compounds with
otent antimicrobial and cytotoxic actions because of
he strong electron withdrawing nature of fluoride and
hloride. Substitution of fluro and chloro groups at the
hird position of the phenyl ring generated compounds
ith more potent antimicrobial and cytotoxic actions
han substitution with a nitro group at that position.
ompounds with a heteroaryl group substitution at
he 4th position of the phenyl ring showed moderate
ntimicrobial and cytotoxic actions. The following
rder was found for the potency of different sub-
tituents at different positions within the phenyl ring at
he 4th position of 1,2,3,4-tetrahydropyrimidines:
-fluoro > 4-chloro > 3-fluoro > 4-pyridyl > 3-
hloro > 3-nitro > 2-chloro > 2-nitro > H. The second
osition sulphur-substituted derivatives of 1,2,3,4-
etrahydropyrimidines were showed most potent
ntimicrobial and cytotoxic effect when compared
ith oxygen atom substituted molecules. Among the
ompounds reported here, compound 7p is arguably
he most potent when compared with the current
herapeutic agents norfloxacin and tamoxifen because
he substitution of fluoride in the phenyl ring present
t the 4th position of 1,2,3,4-tetrahydropyrimidine
nhances the antimicrobial and cytotoxic actions of
ompound 7p (Figs. 3 and 4 and Table 1).
.  Conclusions
A series of novel 1,2,3,4-tetrahydropyrimidines of
iological interest were synthesized, and their structures
ere analyzed. A compound library was prepared using
aboratory prepared chlorosulphonic acid as an efficient
atalyst as compared to Lewis acid. The incorpora-
ion of sulphanilamide into 1,2,3,4-tetrahydropyrimidine
nhanced its antimicrobial and cytotoxic potencies. The
ntimicrobial and cytotoxicity assays showed that all
ynthesized compounds were active against the Gram-
ositive bacteria B.  subtilis, the Gram-negative bacteria
. coli  and Vero Cells. The investigated compounds
howed a range of antimicrobial and cytotoxic activities
hat could be categorized as weak, moderate, or high.
ompared to the antimicrobial and cytotoxic actions of
orfloxacin and tamoxifen, compound 7p was the most
otent compound of those developed in this study. Thus,
[ersity for Science 11 (2017) 46–56 55
we generated interesting compounds when compared
to the current therapeutic agents, and these compounds
should be considered candidates for further investigation
for therapeutic use.
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